Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CLNNW 
Clene Inc (CLNNW)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/11/2025: CLNNW (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -70% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 07/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 646.98M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.48 | 52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 |
52 Weeks Range 0.02 - 0.08 | Updated Date 05/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5032.1% |
Management Effectiveness
Return on Assets (TTM) -49.62% | Return on Equity (TTM) -1738.36% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating 6140786 |
Shares Outstanding - | Shares Floating 6140786 | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Clene Inc
Company Overview
History and Background
Clene Inc., founded in 2012, is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases using a unique nanocatalysis platform. They are publicly traded on the Nasdaq under the ticker symbol CLNN.
Core Business Areas
- Neurodegenerative Disease Therapeutics: Clene focuses on developing drugs to treat neurodegenerative diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), and Parkinson's disease, using their proprietary catalytic nanocrystal platform.
Leadership and Structure
Rob Etherington is the current CEO. The company has a board of directors that oversees corporate governance. The operational structure involves research and development, clinical trials, and regulatory affairs divisions.
Top Products and Market Share
Key Offerings
- CNM-Au8: CNM-Au8 is Clene's lead drug candidate, an oral suspension of gold nanocrystals being developed for the treatment of neurodegenerative diseases such as multiple sclerosis and amyotrophic lateral sclerosis. There is not a publicly known market share for CNM-Au8 since it is not approved. Main competitors include disease-modifying therapies offered by pharmaceutical giants like Biogen (BIIB) and Novartis (NVS).
Market Dynamics
Industry Overview
The biopharmaceutical industry focused on neurodegenerative diseases is characterized by high unmet needs, substantial research and development investment, and rigorous regulatory requirements. The industry is highly competitive, with numerous companies pursuing novel therapies.
Positioning
Clene is positioned as an innovator using nanocatalysis to address neurodegenerative diseases. Its competitive advantage lies in its unique drug delivery system and potential to improve neuronal bioenergetics.
Total Addressable Market (TAM)
The global market for neurodegenerative disease therapeutics is projected to reach hundreds of billions of dollars. Clene aims to capture a portion of this market with its novel nanocatalytic therapies. Expected to reach $53.9 billion by 2030.
Upturn SWOT Analysis
Strengths
- Novel nanocatalysis platform
- Proprietary drug delivery technology
- Potential for improved bioenergetics
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on successful clinical trial outcomes
- Lack of approved products
- High R&D expenses
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Increased awareness of neurodegenerative diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established therapies
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- NVS
- TEVA
Competitive Landscape
Clene faces significant competition from established pharmaceutical companies with approved therapies. Clene's competitive advantage lies in its novel nanocatalysis approach, which has the potential to provide superior efficacy and safety compared to existing treatments.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by the progression of clinical trials, not revenue generation.
Future Projections: Future growth is dependent on successful clinical trial results, regulatory approvals, and commercialization efforts. Analyst expectations are varied due to the speculative nature of clinical-stage companies.
Recent Initiatives: Recent strategic initiatives include advancing clinical trials of CNM-Au8 in multiple sclerosis and ALS.
Summary
Clene Inc. is a high-risk, high-reward clinical-stage biopharmaceutical company. Its success depends on the successful development and commercialization of CNM-Au8 and other therapies utilizing its nanocatalysis platform. Positive clinical trial outcomes are essential for its future. Clene should focus on partnering and strategic funding to mitigate financial risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Clene Inc. Investor Relations
- SEC Filings
- Analyst Reports
- Company Website
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Investment decisions should be based on individual risk tolerance and thorough due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Clene Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2020-12-31 | CEO, President & Director Mr. Robert Etherington MBA | ||
Sector Consumer Defensive | Industry Packaged Foods | Full time employees 75 | Website https://clene.com |
Full time employees 75 | Website https://clene.com | ||
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.